Fentanyl Users Consume Daily Doses Equivalent to 9,000mg of Morphine, UCLA Study Finds

The scale of fentanyl tolerance among people who use the drug regularly is far beyond what clinical protocols were designed to handle, according to new research from UCLA. A study published in the peer-reviewed journal Drug and Alcohol Dependence found that individuals using illicit fentanyl in Los Angeles consume daily quantities equivalent to nearly 9,000 milligrams of morphine — doses hundreds of times higher than what hospitals administer for pain management.

The findings help explain a mystery that has frustrated addiction treatment providers since fentanyl displaced heroin as the dominant street opioid: why so many patients struggle to start and stay on medications for opioid use disorder, even though methadone and buprenorphine are highly effective at reducing overdose mortality when patients can tolerate them.

Quantifying the Unquantifiable

Researchers at Drug Checking Los Angeles, a public health program founded by UCLA associate professor Chelsea Shover, set out to measure something addiction medicine had largely treated as unknowable: the actual exposure levels of people using illicit fentanyl. Using morphine milligram equivalence (MME) — a standardized metric that enables comparison between opioids of different potencies — the team analyzed purity data from over 500 fentanyl samples collected between September 2023 and January 2026, combined with surveys of 47 regular fentanyl users about their consumption patterns.

The result was striking: an average daily intake of 8,887 MME per person.

To put that figure in context, hospital patients receiving fentanyl for surgical pain or cancer typically receive doses equivalent to 25 to 100 MME per day. The street fentanyl exposure documented in the study exceeds clinical doses by roughly 100 to 350 times.

"We had been treating illicit-opioid doses as a black box — an unknowable, a curiosity," said lead author Morgan Godvin, who drew on her own experience with opioid use disorder to shape the research questions. "Public health has precise quantification methods for other exposures, such as for tobacco or alcohol. If at the molecular level, fentanyl is fentanyl, we should be able to quantify exposure. The results surprised us all."

Why Tolerance Matters for Treatment

The clinical implications of these tolerance levels are significant. Medication-assisted treatment works by occupying opioid receptors with medications like methadone or buprenorphine, reducing cravings and withdrawal symptoms while blocking the euphoric effects of illicit opioids. But initiating MAT requires patients to be in moderate withdrawal — a safety measure to prevent precipitated withdrawal, a severe syndrome that occurs when buprenorphine displaces full agonist opioids too quickly.

For someone whose body has adapted to 9,000 MME daily, achieving sufficient withdrawal to safely start buprenorphine means enduring days of severe symptoms that would be unmanageable for most people. Standard protocols developed during the heroin era, when daily exposure might equal 200 to 400 MME, were not designed for this magnitude of physical dependence.

"This isn't simply a matter of willpower or motivation," said Shover, the study's senior author. "We're asking people to tolerate withdrawal symptoms that are orders of magnitude more severe than what previous generations of patients experienced. The physiology has changed, and our treatment protocols need to adapt."

A Pattern of Failed Inductions

The study's findings align with what clinicians across the country have observed anecdotally. Since 2020, as fentanyl became ubiquitous in the U.S. drug supply, providers have reported increasing rates of failed MAT inductions — patients who attempt to start treatment but abandon it because they cannot endure the withdrawal required.

Some programs have responded by extending the observation period before buprenorphine initiation, using higher initial doses, or switching patients to methadone, which has different pharmacological properties and can sometimes be started more gradually. But these adaptations have been largely improvised, informed by clinical intuition rather than quantitative data about what patients are actually consuming.

The UCLA research provides that missing baseline, offering the first peer-reviewed estimate of street fentanyl exposure in MME terms.

Beyond the Numbers

The study also illuminates why fentanyl has proven so difficult to displace from the illicit drug market. At these consumption levels, physical dependence becomes extraordinarily severe. The withdrawal syndrome — already described by patients as the worst flu imaginable multiplied by ten — becomes potentially dangerous, with risks of dehydration, electrolyte imbalance, and cardiovascular stress.

For people using fentanyl to avoid withdrawal rather than to achieve euphoria, the prospect of days of incapacitating sickness creates a powerful barrier to seeking help. When standard MAT protocols require patients to be in moderate withdrawal before starting medication, that barrier becomes nearly insurmountable for some.

Toward New Protocols

Addiction medicine researchers have been developing alternative approaches to address these challenges. Microdosing buprenorphine — starting with tiny amounts while the patient continues using fentanyl, then gradually increasing — allows the body to adapt without precipitated withdrawal. Some programs use ketamine or other adjunct medications to manage withdrawal symptoms during the induction period. Others are exploring extended inpatient stays for stabilization.

But these approaches remain exceptions rather than standards of care, and access varies widely by geography, insurance status, and program philosophy.

The UCLA findings suggest that adapting MAT protocols to the fentanyl era will require more than incremental adjustments. The hundred-fold increase in tolerance documented in the study represents a qualitative shift in the nature of opioid dependence — one that may demand new medication formulations, new induction strategies, and new expectations about what successful treatment looks like.

The Broader Context

The study arrives as the United States records its third consecutive year of declining overdose deaths — a trend attributed partly to expanded naloxone distribution and increased MAT access. But those gains remain fragile, and fentanyl continues to kill tens of thousands of Americans annually.

Understanding the scale of exposure, Godvin argues, is essential to designing interventions that can reach the people at greatest risk. "We can't treat what we don't measure. For years, we've known fentanyl is more potent than heroin, but 'more potent' is vague. Now we have numbers. And those numbers tell us that business as usual won't work."

For policymakers, the study adds urgency to ongoing debates about treatment access. If initiating MAT requires specialized protocols that many existing programs are not equipped to provide, expanding the treatment workforce means more than simply recruiting more prescribers — it means retraining the entire field in approaches appropriate for the fentanyl era.

The overdose crisis, in other words, has entered a new phase. The drug has changed. The physiology of dependence has changed. Whether treatment can change fast enough to keep pace remains the open question.